Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
| Revenue (TTM) | $191.44M |
| Gross Profit (TTM) | $171.04M |
| EBITDA | $155.14M |
| Operating Margin | 94.40% |
| Return on Equity | 94.70% |
| Return on Assets | 49.20% |
| Revenue/Share (TTM) | $0.99 |
| Book Value | $1.32 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 4.55 |
| EV/Revenue | 4.056 |
| EV/EBITDA | 4.83 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10055.00% |
| Shares Outstanding | $197.54M |
| Float | $122.89M |
| % Insiders | 20.46% |
| % Institutions | 72.01% |
Volatility is currently expanding
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABUS and any ticker you trade — then tracks every position and per-strategy win rate.
